222 related articles for article (PubMed ID: 37622400)
21. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.
Lasagna-Reeves CA; Clos AL; Castillo-Carranza D; Sengupta U; Guerrero-Muñoz M; Kelly B; Wagner R; Kayed R
Biochem Biophys Res Commun; 2013 Jan; 430(3):963-8. PubMed ID: 23261448
[TBL] [Abstract][Full Text] [Related]
22. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.
Xu J; Reumers J; Couceiro JR; De Smet F; Gallardo R; Rudyak S; Cornelis A; Rozenski J; Zwolinska A; Marine JC; Lambrechts D; Suh YA; Rousseau F; Schymkowitz J
Nat Chem Biol; 2011 May; 7(5):285-95. PubMed ID: 21445056
[TBL] [Abstract][Full Text] [Related]
23. Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding.
Wang G; Fersht AR
Proc Natl Acad Sci U S A; 2015 Feb; 112(8):2443-8. PubMed ID: 25675527
[TBL] [Abstract][Full Text] [Related]
24. Contribution of p53, p63, and p73 to the developmental diseases and cancer.
Tomkova K; Tomka M; Zajac V
Neoplasma; 2008; 55(3):177-81. PubMed ID: 18348649
[TBL] [Abstract][Full Text] [Related]
25. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
[TBL] [Abstract][Full Text] [Related]
26. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
[TBL] [Abstract][Full Text] [Related]
27. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
28. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1.
Domínguez G; García JM; Peña C; Silva J; García V; Martínez L; Maximiano C; Gómez ME; Rivera JA; García-Andrade C; Bonilla F
J Clin Oncol; 2006 Feb; 24(5):805-15. PubMed ID: 16380414
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of p53 protein aggregation as a cancer treatment strategy.
Kwan K; Castro-Sandoval O; Gaiddon C; Storr T
Curr Opin Chem Biol; 2023 Feb; 72():102230. PubMed ID: 36436275
[TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
31. Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma.
Anselmo NP; Rey JA; Almeida LO; Custódio AC; Almeida JR; Clara CA; Santos MJ; Casartelli C
Genet Mol Res; 2009 Oct; 8(4):1257-63. PubMed ID: 19876867
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC.
Zhang Y; Xu L; Chang Y; Li Y; Butler W; Jin E; Wang A; Tao Y; Chen X; Liang C; Huang J
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):160-171. PubMed ID: 31471556
[TBL] [Abstract][Full Text] [Related]
33. The dominant-negative interplay between p53, p63 and p73: A family affair.
Billant O; Léon A; Le Guellec S; Friocourt G; Blondel M; Voisset C
Oncotarget; 2016 Oct; 7(43):69549-69564. PubMed ID: 27589690
[TBL] [Abstract][Full Text] [Related]
34. Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line.
Goldschneider D; Blanc E; Raguénez G; Barrois M; Legrand A; Le Roux G; Haddada H; Bénard J; Douc-Rasy S
J Cell Sci; 2004 Jan; 117(Pt 2):293-301. PubMed ID: 14676279
[TBL] [Abstract][Full Text] [Related]
35. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487
[TBL] [Abstract][Full Text] [Related]
36. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression.
van Meyel DJ; Ramsay DA; Casson AG; Keeney M; Chambers AF; Cairncross JG
J Natl Cancer Inst; 1994 Jul; 86(13):1011-7. PubMed ID: 8007011
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines.
Zaika AI; Kovalev S; Marchenko ND; Moll UM
Cancer Res; 1999 Jul; 59(13):3257-63. PubMed ID: 10397274
[TBL] [Abstract][Full Text] [Related]
38. Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation.
De Smet F; Saiz Rubio M; Hompes D; Naus E; De Baets G; Langenberg T; Hipp MS; Houben B; Claes F; Charbonneau S; Delgado Blanco J; Plaisance S; Ramkissoon S; Ramkissoon L; Simons C; van den Brandt P; Weijenberg M; Van England M; Lambrechts S; Amant F; D'Hoore A; Ligon KL; Sagaert X; Schymkowitz J; Rousseau F
J Pathol; 2017 May; 242(1):24-38. PubMed ID: 28035683
[TBL] [Abstract][Full Text] [Related]
39. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Viotti J; Duplan E; Caillava C; Condat J; Goiran T; Giordano C; Marie Y; Idbaih A; Delattre JY; Honnorat J; Checler F; Alves da Costa C
Oncogene; 2014 Apr; 33(14):1764-75. PubMed ID: 23644658
[TBL] [Abstract][Full Text] [Related]
40. The p53R172H mutant does not enhance hepatocellular carcinoma development and progression.
Ahronian LG; Driscoll DR; Klimstra DS; Lewis BC
PLoS One; 2015; 10(4):e0123816. PubMed ID: 25885474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
